The BeOne Medicines Ltd. (ONC) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and other documents filed with the Securities and Exchange Commission. BeOne is a Switzerland‑domiciled global oncology company whose American Depositary Shares are registered with the SEC, while its ordinary shares trade on the Hong Kong Stock Exchange and it also reports to the STAR Market in Shanghai.
Through its filings, BeOne reports on financial results, material agreements and corporate events. BeOne Medicines Ltd.'s recent Forms 8-K announced quarterly financial results, describing revenue growth driven primarily by BRUKINSA product sales and contributions from TEVIMBRA and in-licensed products. Other 8‑K filings detail a royalty purchase agreement with Royalty Pharma tied to royalty rights on IMDELLTRA (tarlatamab) ex‑China net revenue, as well as the creation of related financial obligations and escrow arrangements.
Additional 8‑K reports cover topics such as the termination of a prior credit facility after arranging new financing, and the appointment and compensation terms of senior research and development leadership. The company also furnishes information about its interim reports filed with the STAR Market, including financial data prepared under China Accounting Standards and summaries of differences from U.S. GAAP.
On Stock Titan, users can review these ONC filings alongside AI‑generated summaries that explain the main points of each document in plain language. This includes highlighting key items in earnings‑related filings, summarizing the structure and implications of material agreements, and pointing out governance or leadership changes disclosed under Item 5.02 of Form 8‑K. Investors can also use the filings page to monitor how BeOne describes its oncology portfolio, collaborations and financial position over time, and to cross‑reference U.S. disclosures with the company’s press releases and non‑U.S. reporting.
Real‑time updates from EDGAR, combined with AI‑assisted overviews, help readers navigate lengthy filings and focus on sections most relevant to their interests, whether they are following BeOne’s hematology and solid tumor programs, its financing arrangements or its multi‑exchange reporting obligations.
Mooney Elizabeth Fisher reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. director Elizabeth Fisher Mooney received an equity grant representing 18,980 Ordinary Shares on a Form 4 filing. These shares underlie restricted share units granted at a price of $0.00 per share as a compensation award rather than a market purchase.
The restricted share units will become fully vested on the earlier of the first anniversary of the grant date or the date of the next annual general meeting. Vesting stops if she resigns from the board or otherwise ceases to serve as a director, unless accelerated under the company’s Independent Non-Executive Director Compensation Policy.
Dugan Margaret reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. director Margaret Dugan received an equity award of 18,980 Ordinary Shares on June 11, 2026, reported at a price of $0.0000 per share. These represent securities underlying restricted share units that vest on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to continued board service and any accelerated vesting provisions under the company’s Independent Non-Executive Director Compensation Policy. Following this grant, Dugan directly holds 73,164 Ordinary Shares.
Sawyers Charles Lazelle reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. director Charles Lazelle Sawyers reported a grant of 18,980 Ordinary Shares as a share-based award. The award represents restricted share units that vest on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to continued board service and any accelerated vesting triggers under the company’s Independent Non-Executive Director Compensation Policy. Following the award, he holds 18,984 Ordinary Shares directly. A separate entry shows 1,946 American Depositary Shares held directly, and each American Depositary Share represents 13 Ordinary Shares.
Sharp Shalini reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. director Shalini Sharp reported a compensation-related equity award. She received 18,980 Ordinary Shares for no cash payment, described as securities underlying restricted share units that vest on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to continued board service and possible accelerated vesting under the company’s Independent Non-Executive Director Compensation Policy. After this award, she directly holds 38,116 Ordinary Shares. A separate line shows direct ownership of 9 American Depositary Shares, with each American Depositary Share representing 13 Ordinary Shares.
Riva Alessandro reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. director Alessandro Riva received a grant of 18,980 ordinary shares in the form of restricted share units at no purchase price. These units vest on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to his continued board service and potential accelerated vesting under the company’s Independent Non-Executive Director Compensation Policy. Following this award, Riva directly holds 73,164 ordinary shares.
BeOne Medicines Ltd. director Charles Lazelle Sawyers filed an initial Form 3 reporting his ownership in the company. He directly holds 1,946 American Depositary Shares and 4 ordinary shares as of June 11, 2026. Each American Depositary Share represents 13 ordinary shares.
BeOne Medicines Ltd. director Elizabeth Fisher Mooney has filed an initial Form 3, which is the required statement of beneficial ownership for new insiders. The filing summary in this excerpt shows no reported purchases, sales, exercises, gifts, restructurings, or other equity transactions and no listed holdings.
Baker Bros. Advisors and related entities report beneficial ownership of approximately 115.9 million Ordinary Shares, representing 8.0% of the Ordinary Shares of the issuer, primarily through American Depositary Shares. The ownership is held across Baker Bros. funds and affiliated entities, with the adviser exercising voting and investment power.
On June 11, 2026, Felix J. Baker, Ph.D. was elected to the issuer’s board of directors as Lead Director, while prior directors and adviser employees Michael Goller and Ranjeev Krishana did not stand for re‑election and left the board. In connection with his election, Felix Baker received 18,980 restricted share units that vest into Ordinary Shares, subject to continued board service. The filing also details option and RSU holdings and clarifies that compensation received by adviser employees serving as directors is for the economic benefit of the Baker funds.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. reported a compensation-related equity grant linked to its board. On June 11, 2026, the company granted 18,980 restricted share units payable solely in ordinary shares to Felix J. Baker in connection with his election to the board under the 2016 Share Option and Incentive Plan. The RSUs vest on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to continued board service. Due to the Baker Bros. fund structure, the RSU grant and resulting ordinary shares are reflected as indirect proportionate pecuniary interests of affiliated funds, with investment adviser Baker Bros. Advisors LP holding voting and dispositive power. The filing also notes indirect and direct holdings of American Depositary Shares, with each ADS representing 13 ordinary shares.
ONC affiliate filed a Section 144 notice to sell 945 ADS. The filing states the ADS arise from restricted stock vesting under a registered plan and lists a planned cash sale with an anticipated sale date of 05/26/2026.
The filing also reports that 212 ADS were sold on 05/22/2026 for $65,632.97. The form bears a filing reference date of 06/15/2026.